TRxADE HEALTH, Inc. (MEDS) AI Stock Analysis
MEDS AI stock analysis summary
AI ResearchTRxADE HEALTH, Inc. (MEDS) is a health services IT company operating a digital drug procurement marketplace and telehealth services. The company generated $8.0M in trailing twelve-month revenue through June 30, 2026, alongside an operating margin of -412.7%. Its stock has declined 89.7% over the past year, closing at $2.63 on October 16, 2026.
- Market cap
- $11.9M
- Revenue (TTM)
- $8.0M
- P/E
- —
- 1Y return
- -89.7% S&P 500 16.8%
- Avg. target
- —
Bull case
- TRxADE HEALTH achieved revenue growth of 28.7% in FY2025, reaching $23.3M.
- The stock trades at a price-to-sales ratio of 1.5x, lower than the median of 4.1x for US-listed Healthcare peers.
- Insiders maintain strong alignment with the company, holding a 44.5% ownership stake.
Bear case
- TRxADE HEALTH posted a net loss of -$101.3M in FY2025, resulting in an EPS of -$64.60.
- The balance sheet reflects negative shareholders' equity of -$19.5M and a current ratio of 0.14 as of June 30, 2026.
- Revenue dropped 77.2% year-over-year in the latest quarter ended June 30, 2026, with trailing twelve-month revenue falling to $8.0M.
What TRxADE HEALTH does
TRxADE HEALTH, Inc. is a health services IT company based in Lutz, Florida, focused on digitalizing the retail pharmacy sector. Formerly known as Trxade Group, Inc. before rebranding in June 2021, the company operates the TRxADE drug procurement marketplace. This platform provides retail pharmacies with drug procurement capabilities, price transparency, and operational tools. Additionally, TRxADE HEALTH offers patient-centric telehealth services under the Bonum Health brand name, which aims to provide patients with access to healthcare professionals to ensure continuity of care and enhance overall health outcomes.
Growth and profitability
TRxADE HEALTH experienced top-line fluctuations alongside steepening losses in recent fiscal periods. Annual revenue fell from $32.8M in FY2022 to $18.1M in FY2024, representing a decline of 44.7%, before recovering 28.7% to $23.3M in FY2025. Between FY2022 and FY2025, revenue registered a compound annual growth rate of -15.6%. Net income deteriorated from -$2.7M in FY2022 to -$6.9M in FY2024 and -$101.3M in FY2025, resulting in FY2025 EPS of -$64.60. In the trailing twelve months ending June 30, 2026, revenue stood at $8.0M with an operating margin of -412.7% and EPS of -$46.68. For the quarter ended June 30, 2026, quarterly revenue fell 77.2% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, TRxADE HEALTH held $2.5M in cash and short-term investments against total debt of $32.6M, resulting in net debt of $30.2M. The company operates with negative equity, reporting shareholders' equity of -$19.5M against total assets of $32.8M. Liquidity remains tight, indicated by a current ratio of 0.14. Cash flow has been negative, with FY2025 operating cash flow and free cash flow both at -$10.9M, while capital expenditures totaled $881,526.
Valuation and performance
At its October 16, 2026 closing price of $2.63, TRxADE HEALTH had a market capitalization of $11.9M and an enterprise value of $42.6M. The stock trades at a price-to-sales ratio of 1.5x, compared to 4.1x for the median of its US-listed Healthcare peers, while its price-to-book multiple is 80.9x. Over the past year, the stock fell 89.7%, significantly lagging the S&P 500 benchmark return of 16.8%. The shares trade 61.2% below their 200-day moving average, between a 52-week high of $73.00 and a 52-week low of $0.82.
What analysts expect
There are no published analyst ratings, consensus price targets, or forward earnings estimates provided for TRxADE HEALTH. The company is scheduled to report its next earnings release on November 18, 2026. Prior financial reports show that the company posted an EPS of -$64.60 in FY2025 and an EPS of -$46.68 over the trailing twelve months ended June 30, 2026.
Key risks and what to watch
- The company's total debt of $32.6M significantly exceeds its cash balance of $2.5M as of June 30, 2026.
- Operating cash burn remains severe after registering operating cash flow of -$10.9M in FY2025.
- High short interest represents a point of market pressure, with short interest accounting for 15.1% of the float.
- Trailing twelve-month operating margin stands at -412.7%, reflecting ongoing operational unprofitability.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this MEDS AI stock analysis
This page is an AI-written research summary of TRxADE HEALTH, Inc. (MEDS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: MEDS income statement, MEDS balance sheet, MEDS key metrics, MEDS chart. See the MEDS stock overview for the latest quote and news.
MEDS AI stock analysis FAQ
What does TRxADE HEALTH do?
TRxADE HEALTH, Inc. operates a digital drug procurement marketplace connecting retail pharmacies with suppliers, alongside telehealth services under the Bonum Health brand name.
When does TRxADE HEALTH report its next earnings?
TRxADE HEALTH is scheduled to release its next quarterly earnings on November 18, 2026.
What is TRxADE HEALTH's debt and cash situation?
As of June 30, 2026, the company held $2.5M in cash and short-term investments against total debt of $32.6M, resulting in net debt of $30.2M.
How has MEDS stock performed recently?
MEDS stock closed at $2.63 on October 16, 2026, representing a one-year decline of 89.7% and a year-to-date decline of 86.8%.